Credit Suisse Reiterates Neutral on Amedisys, Maintains $101 Price Target
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Jonathan Yong has reiterated a Neutral rating on Amedisys (NASDAQ: AMED) and maintained a price target of $101.
July 27, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Amedisys' stock rating has been reiterated as Neutral by Credit Suisse, with a maintained price target of $101.
The reiteration of a Neutral rating by Credit Suisse indicates that the analyst sees the stock as fairly valued at its current price. The maintained price target of $101 suggests that the analyst does not expect significant price movement in the short term. This could lead to a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100